Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...

A 3-hour WHO Hantavirus emergency Zoom call was held this morning, providing outbreak analysis. It seemed that for every ...

Bank of America Global Healthcare Conference 2026 May 13, 2026 2:20 PM EDTCompany ParticipantsDouglas Love - CEO, President ...

Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a ...

Biogen’s Apellis acquisition consolidates a complement franchise spanning retinal and renal indications, with near-term label ...

Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...

Among hospitalized adults with acute exacerbation of COPD, pegtarazimod improved oxygen utilization and inflammatory ...

Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Claseprubart granted ...

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people ...

Consolidated net revenue of € 713.4 million in the first quarter of 2026, +4.9% or +8.7% on a like-for-like basis(3) at constant exchange rates ...

The first quarter 2026 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 PM CET/8:30 AM ET. A webcast of the live call may be ...

White blood cells called neutrophils act as factories for C4A, linking peripheral immunity to schizophrenia and synaptic pruning.